Can Vancevi be reimbursed by medical insurance? Domestic and foreign medical insurance policies are very different

Valcyte, whose generic name is valganciclovir (Valganciclovir), is a highly effective antiviral drug against cytomegalovirus (CMV) infection. It is especially suitable for organ transplant recipients or patients with low immune function. Although the drug is already on the Chinese market, unfortunately, it has not yet been included in the national medical insurance directory, which means that patients need to pay for it in full out of pocket.

As of now, Vancevir has not been included in the reimbursement scope of the national medical insurance, and domestic patients have to bear the high cost of purchasing this drug. As an original research drug, Vancevi is expensive. One box (450mg*60tablets) costs about more than 10,000 yuan. Although some areas may provide local medical insurance reimbursement for specific groups or diseases, in general, Vancevi is not a drug universally covered by medical insurance. Patients can consult the local medical insurance department or hospital to find out whether there are relevant local reimbursement policies.

In contrast, in some other countries, Vancevir has been included in medical insurance or insurance coverage, especially for high-risk groups such as organ transplant patients and people with HIV-related cytomegalovirus infection. These patients have clear treatment needs and long-term medication costs are high. Therefore, in order to reduce their financial burden, some countries have included Vancevir in their medical insurance. However, specific policies vary from country to country, and you need to refer to each country’s medical insurance regulations.

For patients under greater financial pressure in the country, some drug charities may provide free or discounted drug support. In addition, patients can also choose legal overseas versions, such as original drugs from India or Turkey. The price is relatively affordable, about three to four thousand yuan, and the drug ingredients and efficacy are consistent with the domestic version. At the same time, patients can also pay attention to the update of the national medical insurance catalog to see whether Vancevi can be included in medical insurance in the future.

Regardless of whether they choose the domestic or foreign version, patients must strictly follow the doctor's instructions and monitor blood indicators regularly during treatment to prevent adverse reactions. For eligible patients, you can negotiate with your doctor to adjust the treatment plan and find more cost-effective drug alternatives.

xa0

Reference materials

"National Medical Insurance Drug Catalog (2023 Edition)" http://www.nhsa.gov.cn/